Observations placeholder
Tamiflu and Relenza
Identifier
005607
Type of Spiritual Experience
Background
A description of the experience
Neuraminidase inhibitors
Neuraminidase inhibitors are a class of antiviral drugs targeted at the influenza virus, which work by blocking the function of the viral neuraminidase protein, thus preventing the virus from reproducing by budding from the host cell.
Unlike the M2 inhibitors, which work only against the influenza A, neuraminidase inhibitors act against both influenza A and influenza B.
Oseltamivir – Tamiflu
Most common Tamiflu side effects
- Abnormal behaviour - (1,190 reports)
- Nausea and vomiting - (790 reports)
- Drug exposure during pregnancy - (693 reports)
- Hallucinations - (659 reports)
- Nausea - (620 reports)
- Fever - (562 reports)
- Diarrhea - (485 reports)
- Rashes - (449 reports)
- Pneumonia - (419 reports)
- The flu - (416 reports)
Zanamivir – Relenza
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed under the trade name Relenza as a powder for oral inhalation.
Most common Relenza side effects
- Abnormal behaviour - (766 reports)
- Overdose - (442 reports)
- Drug exposure during pregnancy - (412 reports)
- Hallucinations - (288 reports)
- Delirium - (218 reports)
- Fever - (189 reports)
- Loss of consciousness - (165 reports)
- Agitation - (157 reports)
- Drug exposure via breast milk - (146 reports)
- Memory loss - (133 reports)
Laninamivir - Inavir
Laninamivir (CS-8958) is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.
Peramivir
Peramivir (trade name Rapivab) is an antiviral drug for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration. On 19 December 2014, the FDA approved peramivir to treat influenza infection in adults.
Peramivir has also been approved in Japan and South Korea and is available in Japan as Rapiacta and in South Korea as Peramiflu. As of 2015, it is the only intravenous option for treating swine flu.
On Jan, 31, 2017 250 people reported to have side effects when taking Oseltamivir Phosphate. Among them, 1 person (0.4%) has Hallucination
On Jan, 30, 2017 13,234 people reported to have side effects when taking Tamiflu. Among them, 659 people (4.98%) have Hallucination
On Jan, 21, 2017 13,234 people reported to have side effects when taking Tamiflu. Among them, 75 people (0.57%) have Hallucination, Auditory
On Jan, 31, 2017 3,544 people reported to have side effects when taking Relenza. Among them, 288 people (8.13%) have Hallucination
On Jan, 31, 2017 3,544 people reported to have side effects when taking Relenza. Among them, 71 people (2.0%) have Hallucination, Auditory
Time on Tamiflu when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Tamiflu :
| Female | Male | |
| Hallucination | 40.64% | 59.36% |
Age of people who have Hallucination when taking Tamiflu :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.56% | 31.96% | 30.84% | 2.80% | 6.73% | 9.91% | 3.36% | 13.83% |
On Mar, 11, 2015: 10,429 people reported to have side effects when taking Tamiflu. Among them, 255 people (2.45%) have Death.
Time on Tamiflu when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |